Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. - Wikidata - awgldk - TriplyDB

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.

http://www.wikidata.org/entity/Q33213561

about

Secondary treatment of acute graft-versus-host disease: a critical review Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.Current and future approaches for control of graft-versus-host disease.Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation.Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15.Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects Tocilizumab for steroid refractory acute graft-versus-host disease Advances in the understanding of acute graft-versus-host disease.Mucosal graft-vs-host disease.Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).Advances in the treatment of acute graft-versus-host disease.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients.Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marr Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children.Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.Daclizumab for children with corticosteroid refractory graft-versus-host disease.Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease

P2860

Q26823275-8D60E86C-0B50-4E92-8C5E-ADF6865501B7 Q33256286-2746D39F-46C5-41D3-9962-A44818F3FE17 Q33642625-ADC7CABD-E932-4B1B-902D-DF6F0E3C00AF Q34184622-9F204D33-DD44-4EE1-8734-9B78A1B71E94 Q34288677-96C79722-8146-404B-8071-C26D45F35C4B Q34441886-AC5C3E4B-2283-4024-ACF1-D81900EEB3B8 Q35638252-8BF1BA18-44BE-42FF-ABC8-A66DE56F2FD7 Q36113205-66A3FF00-8F58-4814-8DBC-D808ED767BAE Q36171750-231BF0E0-F688-472E-A197-4D7C15EFC7CA Q36380188-7A53DB53-9B93-44A5-B230-8DB6D1D1C34B Q36422339-131E7928-352E-4329-8E08-02912A53298C Q36759581-0A0EDCA9-DE42-40B4-87CB-8EADD16A835D Q36974835-A39231C0-7BD0-478F-85B4-ADFB273B4ACD Q37127527-0CC7D963-F311-4AA0-B737-F0C1457CDC03 Q37191057-259965F1-C377-49CA-9A4B-7D266788387D Q37810286-19550CF8-E8D6-4102-A662-112BCEB4DE35 Q37851519-6002CDD5-C117-489A-AD80-5F7F4056C7EC Q38066586-CCBF966E-69B4-4154-B94A-AA103090B6D9 Q38839140-448D1284-0B39-4341-82B2-9EFF6C40DA24 Q44397466-F8401555-2B51-4A1C-8020-9D200ABAEA08 Q46584471-0D000034-0385-45DB-BB1E-80EAF234B72E Q46890990-BADBEF6A-B5F8-4E2E-9A52-6B6B300AF452 Q47137561-8532CA32-FCAC-4C9C-BCA9-47F0E635BE79 Q53652051-6E18DA5E-78EA-4D2C-92E8-0880E78BD795 Q57252632-FDDF6CA3-46B5-450E-BAA2-9BF2EA45B6B4

P2860

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.

http://www.wikidata.org/entity/Q33213561

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@ast

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@en

type

label

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@ast

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@en

prefLabel

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@ast

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@en

P1433

Q33213561-803D1D20-EC06-4593-980C-20A03480CC21

P1476

Q33213561-0E0591D4-8179-4EC9-87C5-978F58A38EFC

P2093

Q33213561-0193B64F-CE59-4DF7-BD27-997D1C3AD753

Q33213561-0CD95D84-0B72-45C8-AD6F-A895C565A4A8

Q33213561-12DAE54F-19C1-454F-A522-212265A03DC2

Q33213561-29F93438-55C2-4898-ABEC-45735CD7B5FD

Q33213561-2CFA6D51-B59D-4771-A2DD-25A12A0016F2

Q33213561-5AC5A00D-6E60-4377-8D13-EED170E9B181

Q33213561-88C8A651-921F-4A5F-8422-30F68076FC03

Q33213561-9408F104-9764-4C17-BDD1-37684A68D287

Q33213561-A842051B-9D14-40F0-86F4-0511DDA1E34A

Q33213561-B6E3EFA8-3D5D-46CF-AD58-D0A813F9BBEC

P2860

Q33213561-25A19020-C80A-4C46-801F-3CCD04562573

Q33213561-40AE48B3-4D08-4871-BF28-D654CF808459

Q33213561-4A021136-F2FA-4E3F-8E8D-F8D9D53B2A3F

Q33213561-54C51ED3-780E-4ECE-AB09-7B647FD2EAE6

Q33213561-55035529-3E15-44BC-9A2A-81C7240BAC3D

Q33213561-5B1DFA0F-1BF5-40E4-AA6A-3BDE915C0D27

Q33213561-5C48FEB5-7234-45A0-A7A1-00782F3B7CA0

Q33213561-64135FDA-D8DE-4186-8E94-25ADB4C27191

Q33213561-77FEB4E1-77C7-4EC4-BA98-5341B2C90DD1

Q33213561-91EAAAD7-5168-4467-B991-DD0E838C77E5

P2888

Q33213561-1F68F2DA-5BA5-402B-BF87-8D26B821DFEA

P304

Q33213561-66711124-F112-4F2A-A6EA-44209F9E20A4

P31

Q33213561-00981E7C-5A79-4C60-958C-2498797115DB

P356

Q33213561-7578BDD7-4295-4950-9B8B-D335FA8E681B

P407

Q33213561-555B1265-6537-4F22-9CC5-3BF7E60E3968

P433

Q33213561-C298EE43-3909-4F35-A695-FB7CAF4F7759

P478

Q33213561-4275084F-DADC-4441-A265-C03AB028CE1E

P577

Q33213561-A25E569A-5687-4364-BFC7-E2C51932C122

P5875

Q33213561-FE73DFCE-7D3B-48B5-9E46-07A9264D2A8F

P6179

Q33213561-F2A2F9F2-BE4A-41B3-BCDB-BE1B5C231486

P698

Q33213561-1A6D7166-57E2-4D25-A661-9394AAC1B1D6

P356

P1433

Bone Marrow Transplantation

P1476

Treatment of steroid-resistant ...... ith daclizumab and etanercept.

@en

P2093

Brenmoehl J

http://www.w3.org/2001/XMLSchema#string

Casper J

http://www.w3.org/2001/XMLSchema#string

Freund M

http://www.w3.org/2001/XMLSchema#string

Hartung G

http://www.w3.org/2001/XMLSchema#string

Hofmeister N

http://www.w3.org/2001/XMLSchema#string

Holler E

http://www.w3.org/2001/XMLSchema#string

Junghanss C

http://www.w3.org/2001/XMLSchema#string

Leithaeuser M

http://www.w3.org/2001/XMLSchema#string

Roessler V

http://www.w3.org/2001/XMLSchema#string

Steiner B

http://www.w3.org/2001/XMLSchema#string

P2860

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.

Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients.

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease.

P2888

P304

1003-1010

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1704929

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7930320

http://www.w3.org/2001/XMLSchema#string

P6179

1045806031

http://www.w3.org/2001/XMLSchema#string

P698

15806135

http://www.w3.org/2001/XMLSchema#string